CA-ANDERSEN-GLOBAL
31.1.2024 18:16:28 CET | Business Wire | Pressemeddelelse
Andersen, den hurtigst voksende uafhængige, multidisciplinære serviceorganisation i verden, har udvidet sin værdiansættelseskapacitet og sit team med tilføjelsen af samarbejdsvirksomheder i Argentina, Chile, Colombia og Mexico. Bekendtgørelsen finder sted i forlængelse af lanceringen af Andersens globale værdiansættelsespraksis og tilføjelsen af værdiansættelseskapaciteter i Brasilien sidste år. Disse tilføjelser styrker organisationens hurtigt voksende platform i regionen, som allerede udbyder skattemæssig og juridisk dækning i mere end 18 lande i hele Latinamerika.
De nye firmaer, der slutter sig til Andersens platform i Latinamerika, inkluderer:
- First Capital Group (Argentina) – First Capital Group har base i Buenos Aires og er et team af finansfolk med over 30 års erfaring i at levere forretningsmæssige og finansielle løsninger, herunder værdiansættelsesydelser.
- Valoriza (Chile) – Med kontorer i Santiago og Miami er Valoriza et uafhængigt firma, der leverer grundige og indsigtsfulde værdiansættelser med fokus på værdiansættelse af virksomheder og M&A for det mellemstore marked.
- Valuaciones de Chile (Chile) – Valuaciones de Chile har base i Santiago og leverer uafhængige værdiansættelsestjenester med fokus på fast ejendom, aktiver samt maskiner og udstyr.
- Confianza (Colombia) – Confianza holder til i Bogota, har specialiseret sig i værdiansættelser af maskiner og udstyr og giver kunder i Latinamerika omfattende støtte til deres finansielle aktiviteter.
- Giron Valuation Services (Mexico) – Giron Valuation Services (GVS), der opererer fra Estado de México, er et team af fagfolk med stor erfaring i at levere værdiansættelser af virksomheder og økonomisk rådgivning til både lokale og globale kunder.
"Værdiansættelse er et vigtigt vækstområde for Andersen, og man kan forvente at se os udvide vores globale værdiansættelsespraksis hastigt på andre vigtige markeder i Latinamerika og globalt," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktør for Andersen.
"Vi er stolte over at arbejde sammen med disse firmaer, når vi udvider vores globale værdiansættelsesservice i Latinamerika," tilføjer Sid Luckenbach, administrerende direktør for Andersens globale værdiansættelsespraksis. "Disse nye firmaer er et stærkt kulturelt match for Andersen og deler vores forpligtelse på uafhængighed, problemfri kundeservice, forvaltning og ekspertise."
Andersens globale værdiansættelsesteam samarbejder med virksomheder, fonde, velhavende privatpersoner og familiekontorer om værdiansættelse af virksomheder, materielle og immaterielle aktiver og komplekse værdipapirer med henblik på skat, finansiel rapportering og transaktionsrådgivning. Andersens kunder spænder over en række brancher med forskellige værdiansættelsesbehov på globalt plan.
"Latinamerika er fortsat et spændende vækstmarked for os," siger Leonardo Mesquita, Andersens regionale administrerende direktør for Latinamerika. "Vores kunder kræver i stigende grad uafhængige værdiansættelser i hele regionen, og vi ser frem til at opfylde deres værdiansættelsesbehov som ét firma."
Andersens globale værdiansættelsespraksis er repræsenteret i mere end 25 lande i Nordamerika, Europa, Latinamerika, Mellemøsten og Asien.
Om Andersen :
Andersen Global er en international sammenslutning af juridisk adskilte og uafhængige medlemsvirksomheder, der består af skatteeksperter og -jurister i hele verden. Andersen Global, der blev etableret i 2013 af den amerikanske medlemsvirksomhed Andersen Tax LLC, har nu mere end 15.000 eksperter i hele verden og en tilstedeværelse på over 425 lokaliteter gennem sine medlems- og samarbejdsvirksomheder.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20240130606657/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
